GlassScriptPhysician profile
Tim T Lai
NPI 1295094324
$1,414.76
in general payments reported to CMS, 2019-2025
14 companies · $73.57 in 2025
The $73.57 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.95 · 2020: $143 · 2021: $429 · 2022: $302 · 2023: $317 · 2024: $134 · 2025: $73.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.88 |
| Education | $251.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $369.12 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $236.12 | 2023 | Ultomiris |
| Biohaven Pharmaceuticals, INC. | $131.91 | 2021 | |
| Novo Nordisk INC | $120.90 | 2021 | |
| Allergan, INC. | $115.30 | 2020 | |
| Insightec,INC | $113.05 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $102.45 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $58.21 | 2019-2021 | |
| Ucb, INC. | $54.88 | 2022-2025 | Rystiggo |
| Pfizer INC. | $44.19 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $22.87 | 2022 | |
| Lilly USA, LLC | $19.43 | 2021 | |
| Sk Life Science, INC. | $13.68 | 2025 | |
| Eisai INC. | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tim Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.